Not sure if this is relevant but... Acorda Therap
Post# of 30028
Posted On: 09/25/2014 8:51:32 AM
Not sure if this is relevant but...
Acorda Therapeutics (ACOR_) said Wednesday it would acquire privately held Civitas Therapeutics in a $525 million cash deal that would provide the buyer access to a late-stage Parkinson's disease treatment.
Ardsley, N.Y.-based Acorda markets three therapies focused on countering neurological disorders. Buying Civitas would give it worldwide rights to CVT-301, a Phase 3 treatment candidate for some Parkinson's complications, as well as rights to Civitas' proprietary pulmonary delivery technology and Chelsea, Mass.-based manufacturing facilities.
Acorda said the treatment for Parkinson's is complicated by challenges in maintaining proper dosing regimen, and that the Civitas drug is designed to treat a rapid return of symptoms common in Parkinson's patients. The drug's Phase 3 study is expected to begin enrollment in early 2015 and, if successful, a filing for regulatory approval in the United States is expected by the end of 2016.
"The acquisition adds an exciting product candidate to Acorda's pipeline that addresses a significant unmet need in Parkinson's disease," Acorda CEO Ron Cohen said in a statement. "It also leverages Acorda's existing development and commercial capabilities and creates an opportunity for us to develop a global presence."
Cohen called the CVT-301 drug "a potentially transformative therapy for people with Parkinson's disease," adding that the company estimates U.S. sales of the drug could exceed $500 million.
As part of the deal, Acorda will make a $35 million payment to cover costs related to a Civitas change-in-control provision. The purchase is expected to close before year's end.
MTS Health Partners LP and Lazard served as Acorda Therapeutics' financial advisers, with a Cadwalader, Wickersham & Taft LLP team including partners Jim Woolery, Christopher Cox, Ira Schacter, Greg Patti, Linda Swartz, Dorothy Auth and Andrew Forman providing legal counsel. Civitas was advised by JPMorgan Chase & Co., Bank of America Merrill Lynch and Ropes & Gray LLP.
David Fox and William Sorabella of Kirkland & Ellis LLP led the team representing MTS Health and Andrew Dickinson and David Low of Lazard, who were financial advisers to Acorda Therapeutics.
Acorda Therapeutics (ACOR_) said Wednesday it would acquire privately held Civitas Therapeutics in a $525 million cash deal that would provide the buyer access to a late-stage Parkinson's disease treatment.
Ardsley, N.Y.-based Acorda markets three therapies focused on countering neurological disorders. Buying Civitas would give it worldwide rights to CVT-301, a Phase 3 treatment candidate for some Parkinson's complications, as well as rights to Civitas' proprietary pulmonary delivery technology and Chelsea, Mass.-based manufacturing facilities.
Acorda said the treatment for Parkinson's is complicated by challenges in maintaining proper dosing regimen, and that the Civitas drug is designed to treat a rapid return of symptoms common in Parkinson's patients. The drug's Phase 3 study is expected to begin enrollment in early 2015 and, if successful, a filing for regulatory approval in the United States is expected by the end of 2016.
"The acquisition adds an exciting product candidate to Acorda's pipeline that addresses a significant unmet need in Parkinson's disease," Acorda CEO Ron Cohen said in a statement. "It also leverages Acorda's existing development and commercial capabilities and creates an opportunity for us to develop a global presence."
Cohen called the CVT-301 drug "a potentially transformative therapy for people with Parkinson's disease," adding that the company estimates U.S. sales of the drug could exceed $500 million.
As part of the deal, Acorda will make a $35 million payment to cover costs related to a Civitas change-in-control provision. The purchase is expected to close before year's end.
MTS Health Partners LP and Lazard served as Acorda Therapeutics' financial advisers, with a Cadwalader, Wickersham & Taft LLP team including partners Jim Woolery, Christopher Cox, Ira Schacter, Greg Patti, Linda Swartz, Dorothy Auth and Andrew Forman providing legal counsel. Civitas was advised by JPMorgan Chase & Co., Bank of America Merrill Lynch and Ropes & Gray LLP.
David Fox and William Sorabella of Kirkland & Ellis LLP led the team representing MTS Health and Andrew Dickinson and David Low of Lazard, who were financial advisers to Acorda Therapeutics.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼